0001104659-21-146421.txt : 20211203 0001104659-21-146421.hdr.sgml : 20211203 20211203171333 ACCESSION NUMBER: 0001104659-21-146421 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211202 FILED AS OF DATE: 20211203 DATE AS OF CHANGE: 20211203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burns John Thomas CENTRAL INDEX KEY: 0001568734 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33958 FILM NUMBER: 211471095 MAIL ADDRESS: STREET 1: 16760 SW UPPER BOONES FERRY RD STREET 2: SUITE 101 CITY: PORTLAND STATE: X1 ZIP: 97224 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SELLAS Life Sciences Group, Inc. CENTRAL INDEX KEY: 0001390478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 6462005278 MAIL ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Galena Biopharma, Inc. DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: GALENA BIOPHARMA, INC. DATE OF NAME CHANGE: 20110922 4 1 tm2134552-4_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-12-02 0 0001390478 SELLAS Life Sciences Group, Inc. SLS 0001568734 Burns John Thomas C/O SELLAS LIFE SCIENCES GROUP, INC. 7 TIMES SQUARE, SUITE 2503 NEW YORK NY 10036 0 1 0 0 VP, Finance & Corp Controller Common Stock 2021-12-02 4 S 0 231 6.2673 D 17644 D Represents the number shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reflects the weighted average sale price of the shares of common stock sold. These shares of common stock were sold in multiple transactions at prices ranging from $6.25 to $6.27, inclusive, per share of common stock. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares of common stock sold at each price. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. /s/ John Burns 2021-12-03